Dennis Maier Net Worth

The estimated Net Worth of Dennis B Maier is at least 712 千$ dollars as of 23 August 2021. Mr. Maier owns over 2,715 units of Artivion Inc stock worth over 316,065$ and over the last 6 years he sold CRY stock worth over 395,972$. In addition, he makes 0$ as Vice President - Operations at Artivion Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Maier CRY stock SEC Form 4 insiders trading

Dennis has made over 4 trades of the Artivion Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,715 units of CRY stock worth 69,613$ on 23 August 2021.

The largest trade he's ever made was selling 7,197 units of Artivion Inc stock on 17 February 2021 worth over 177,982$. On average, Dennis trades about 1,115 units every 18 days since 2019. As of 23 August 2021 he still owns at least 17,677 units of Artivion Inc stock.

You can see the complete history of Mr. Maier stock trades at the bottom of the page.

Dennis Maier biography

Dennis B. Maier serves as Vice President - Operations of the Company. He was appointed to the position of Vice President, Operations in July 2017. Mr. Maier has more than 15 years in the medical device industry. Prior to joining CryoLife, he served as the Senior Director of Baxter Healthcare’s direct material global purchasing and supplier management team. He also served as Vice President of Global Sourcing for Hill-Rom. Prior to that, he spent five years with Medtronic leading several Cardiac Rhythm Disease Management (CRDM) manufacturing operations, as well as serving as Director of CRDM Global Commodity management. Mr. Maier also spent eight years with Abbott Vascular and Boston Scientific (both former Guidant Corporation businesses) in a variety of leadership roles. Prior to entering the medical device industry, Mr. Maier worked briefly for Ford Motor Company and served six years as an officer in the U.S Army. He received an MBA from the Krannert Graduate School of Management at Purdue University and a Bachelor of Science in Mechanical Engineering from the U.S. Military Academy at West Point.

How old is Dennis Maier?

Dennis Maier is 46, he's been the Vice President - Operations of Artivion Inc since 2017. There are 23 older and no younger executives at Artivion Inc. The oldest executive at Artivion Inc is Ronald McCall, 83, who is the Presiding Independent Director.

What's Dennis Maier's mailing address?

Dennis's mailing address filed with the SEC is 1655 ROBERTS BLVD, NW, , KENNESAW, GA, 30144.

Insiders trading at Artivion Inc

Over the last 21 years, insiders at Artivion Inc have traded over 18,346,910$ worth of Artivion Inc stock and bought 91,700 units worth 1,086,548$ . The most active insiders traders include Steven G Anderson、Thomas F Ackerman、James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of 211,842$. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth 46,425$.

What does Artivion Inc do?

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.

Complete history of Mr. Maier stock trades at Artivion Inc

Artivion Inc executives and stock owners

Artivion Inc executives and other stock owners filed with the SEC include:

• James Mackin,
  Chairman of the Board, President, Chief Executive Officer, Director
• D. Ashley Lee,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Jean Holloway,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Michael Simpson,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• John Davis,
  Senior Vice President - Global Sales and Marketing
• James Patrick Mackin,
  Chairman, Pres & CEO
• Scott Capps,
  Vice President - Clinical Research
• David Ashley Lee CPA, CPA,
  Exec. VP, COO & CFO
• Jean F. Holloway Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• John E. Davis,
  Sr. VP of Global Sales & Marketing
• Harvey Morgan,
  Independent Director
• Daniel Bevevino,
  Independent Director
• Ronald McCall,
  Presiding Independent Director
• Thomas Ackerman,
  Independent Director
• Jon Salveson,
  Independent Director
• James Bullock,
  Independent Director
• Jeffrey Burbank,
  Independent Director
• Marna Borgstrom,
  Independent Director
• Greg Chodaczek,
  IR Contact Officer
• Matthew Getz,
  Vice President - Human Resources
• Dennis Maier,
  Vice President - Operations
• Amy Horton,
  Chief Accounting Officer, Vice President
• Thomas Bogenschutz,
  Senior Vice President - EMEA, General Manager - Hechingen
• Dr. Marshall S. Stanton,
  Sr. VP of Clinical Research & Chief Medical Officer
• Joshua Wells,
  Sr. Director of Bus. Devel.
• Matthew A. Getz,
  VP of HR
• Amy D. Horton CPA, CPA,
  VP & Chief Accounting Officer
• Sherry M Saurini,
  VP, Quality
• C Elkins Ronald,
  Director
• James Benson,
  Director
• James M Mc Dermid,
  SVP, CHRO
• David C Gale,
  VP-Research and Development
• William Robert Matthews,
  Senior VP, Operations, Quality
• Thomas J Bogenschuetz,
  VP, EMEA & General Manager
• Bruce G. Anderson,
  VP, US Sales and Marketing
• Jeffrey W Burris,
  Vice President & Gen. Counsel
• Gerald B Seery,
  Sr. VP, Sales and Marketing
• John M Cook,
  Director
• David P. Lang,
  Sr. VP, Intl Sales & Marketing
• Steven G Anderson,
  President, CEO and Chairman
• Thomas J Lynch,
  VP - Reg. Aff./Quality Assur.
• Capital Management Oss,
  10% owner
• Philip A Theodore,
  VP, General Counsel
• Michaelstark Brian Jay Roth,
  
• Sidney B Ashmore,
  Vice President of Marketing
• Virginia C Lacy,
  Director
• Dyne Bruce J Md Van,
  Director
• Albert E Heacox,
  Sr. VP-Laboratory Operations
• Vander James C Wyk,
  VP - Product Integrity
• Kirby S Black,
  Sr. Vice President, R&D
• David Fronk,
  VP - Clinical Research
• Rochelle L. Maney,
  VP, Quality
• Franz Peter Barthold,
  VP, Research & Development
• Marshall S. Stanton,
  SVP, Clinical & MD Affair
• Anthony B. Semedo,
  Director